Braeburn Discusses BRIXADI® Study and Fentanyl’s Impact on OUD

In this portion of the Pharmaceutical Executive Video Interview, Braeburn’s Chief Medical Officer Joshua M. Cohen, MD, MPH, FAHS, discusses the Phase 3 trial data recently published in JAMA and his confidence that these results can be generalized to real-world care settings.